

<!DOCTYPE html>
<html lang="es">
<head>
    <meta charset="UTF-8">  
    <link rel="icon" href="dc3.png" type="image/png">  
    <script src="https://cdnjs.cloudflare.com/ajax/libs/html2pdf.js/0.9.2/html2pdf.bundle.min.js"></script>
    <script src="https://cdn.jsdelivr.net/npm/sweetalert2@10"></script>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>White Book</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0-beta3/css/all.min.css">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@700&display=swap">
    <!-- Estilos para dispositivos móviles -->
    <link rel="stylesheet" href="/commons/presentation/css/estilo_informeM.css?v=1.9&_=${new Date().getTime()}" media="only screen and (max-width: 768px)">
    <!-- Estilos para pantallas de PC -->
    <link rel="stylesheet" href="/commons/presentation/css/estilo_informeM.css?v=1.9&_=${new Date().getTime()}" media="only screen and (min-width: 769px)">
    <script src="https://cdnjs.cloudflare.com/ajax/libs/pdf.js/2.10.377/pdf.min.js"></script>
    <script type="text/javascript" src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script>
     <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    

    <!-- Metadatos Open Graph -->
    <meta property="og:title" content="YOU TOMORROW">
    <meta property="og:description" content="Ofrecemos un estudio en profundidad de las propiedades genéticas de nuestros participantes.">
    <meta property="og:image" content="https://drive.google.com/file/d/1ZZI3G6Fit_kovvVZolrvchtXQQDrnWYI/view?usp=sharing">
    <meta property="og:url" content="https://ytomorrow.com/">
    <meta property="og:type" content="website">

    <!-- Otros metadatos -->
    <meta name="description" content="Ofrecemos un estudio en profundidad de las propiedades genéticas de nuestros participantes.">
    <meta name="keywords" content="you, YOU TOMORROW, TOMORROW, TOMORR, TOM, web">

    <style>

   body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    font-size: 17px;
    line-height: 1.4;
    margin: 20px;
    font-weight: 500; /* Grosor medio de la negrita */
    color: #4a4a4a; /* Gris oscuro elegante */
}

h1, h2, h3 {
    color: #4a4a4a; /* Gris oscuro elegante */
}

h1 {
    font-size: 24px;
}

h2 {
    font-size: 20px;
}

h3 {
    font-size: 18px;
}

p {
    margin-bottom: 12px;
    font-size: 18px;
    color: #4a4a4a; /* Gris oscuro elegante */
}

.section {
    margin-bottom: 30px;
    color: #4a4a4a; /* Gris oscuro elegante */
}

.chart-container {
    display: flex;
    flex-direction: column;
    align-items: center;
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    color: white;
    width: 100%;
}

.chart-row {
    display: flex;
    justify-content: center;
    margin: 10px 0;
    width: 50%; /* Ajusta el ancho para que se adapte al contenido */
}

.chart-box {
    background: linear-gradient(135deg, #42a5f5, #1e88e5);
    padding: 10px 20px;
    margin: 0 5px;
    border-radius: 12px;
    text-align: center;
    font-size: 18px;
    box-shadow: 0px 4px 6px rgba(0, 0, 0, 0.1);
    display: flex;
    align-items: center;
    justify-content: center;
    transition: transform 0.3s ease;
    position: relative;
    overflow: hidden;
    min-width: 150px; /* Asegura que las tarjetas tengan un ancho mínimo */
    max-width: 300px; /* Limita el ancho máximo para tarjetas largas */
    word-wrap: break-word; /* Permite que el texto se ajuste dentro de la tarjeta */
    flex: 1; /* Permite que las tarjetas se expandan uniformemente */
}

.chart-box:hover {
    transform: scale(1.05);
}

.chart-box.ceo {
    background: linear-gradient(135deg, #ff6f61, #e53935);
    font-weight: bold;
    font-size: 22px;
}

.chart-box::before {
    content: '';
    position: absolute;
    top: -50%;
    left: -50%;
    width: 200%;
    height: 200%;
    background: rgba(255, 255, 255, 0.1);
    opacity: 0;
    transition: opacity 0.3s ease;
    transform: rotate(45deg);
}

.chart-box:hover::before {
    opacity: 1;
}

.chart-box.ceo::before {
    background: rgba(255, 255, 255, 0.2);
}

.connector {
    width: 2px;
    height: 20px;
    background-color: #1b3a7a;
    margin: 0 auto;
}

.horizontal-connector {
    height: 2px;
    width: 100%;
    background-color: #1b3a7a;
}

.horizontal-connector.long {
    width: 50%;
}

.chart-box i {
    margin-right: 8px;
    font-size: 20px;
    color: rgba(255, 255, 255, 0.8);
}


table {
    width: 100%;
    border-collapse: collapse;
    margin-bottom: 20px;
  }
  
  table, th, td {
    border: 1px solid #ddd;
  }

  th, td {
    padding: 12px;
    text-align: center;
  }

  th {
    background-color: #1b5e20;
    color: #1b5e20;
    font-weight: bold;
  }

  tr:nth-child(even) {
    background-color: #f2f2f2;
  }

  tr:hover {
    background-color: #ddd;
  }

  caption {
    caption-side: top;
    font-size: 18px;
    font-weight: bold;
    margin-bottom: 10px;
  }

    </style>

</head>
<body>
<div class="container">
REFERENCES
    <ol>

        REFERENCES.
1.Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2018:CIR0000000000000625.
2.Nicholls SJ. The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. Current cardiology reports. 2019;21(4):18.
3.Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovascular Research. 2019;115(3):e26-e31.
4.Elhomsy G. Apolipoprotein B. Medscape. Laboratory Medicine Web site. https://emedicine.medscape.com/article/2087335-overview#a4. Published 2014. Accessed 04/22/19.
5.Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018:25709.
6.Di Donna L, De Luca G, Mazzotti F, et al. Statin-like principles of bergamot fruit (Citrus bergamia): isolation of 3-hydroxymethylglutaryl flavonoid glycosides. J Nat Prod. 2009;72(7):1352-1354.
7.Häggström M RD. Diagram of the pathways of human steroidogenesis. In: pathways S, ed. WikiJournal of Medicine 1 (1)2014.
8.Alberts B, Johnson A, Lewis J ea. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. The Lipid Bilayer. In:2002: https://www.ncbi.nlm.nih.gov/books/NBK26871/. Accessed 03/12/2019.
9.Fardella CE, Miller WL. Molecular biology of mineralocorticoid metabolism. Annu Rev Nutr. 1996;16(1):443-470.
10.Xu K, Morgan KT, Todd Gehris A, Elston TC, Gomez SM. A whole-body model for glycogen regulation reveals a critical role for substrate cycling in maintaining blood glucose homeostasis. PLoS computational biology. 2011;7(12):e1002272-e1002272.
11.Salter AM, Brindley DN. The biochemistry of lipoproteins. Journal of inherited metabolic disease. 1988;11 Suppl 1:4-17.
12.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
13.Feingold KR, Grunfeld C. Introduction to Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.
14.Lagor W, Millar J. Overview of the LDL receptor: relevance to cholesterol metabolism and future approaches to the treatment of coronary heart disease. JRLCR. 2009;3:1-14.
15.Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992;93(3):189-199.
16.Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993;94(4):350-356.
17.Liu ML, Ylitalo K, Salonen R, Salonen JT, Taskinen MR. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arteriosclerosis, thrombosis, and vascular biology. 2004;24(8):1492-1497.
18.Koba S, Yokota Y, Hirano T, et al. Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. Journal of atherosclerosis and thrombosis. 2008;15(5):250-260.
19.Rubenfire M, American College of Cardiology. Lipoprotein(a): Diagnosis, Prognosis, Emerging Therapies. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/02/07/14/21/a-test-in-context-lipoproteina-diagnosis. Published 2017. Accessed Jun. 27, 2019.
20.Schettler VJJ, Neumann CL, Peter C, et al. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Clinical research in cardiology supplements. 2019;14(Suppl 1):33-38.
21.Thanassoulis G. Screening for High Lipoprotein(a): The Time Is Now. Circulation. 2019;139(12):1493-1496.
22.Borrelli MJ, Youssef A, Boffa MB, Koschinsky ML. New Frontiers in Lp(a)-Targeted Therapies. Trends Pharmacol Sci. 2019;40(3):212-225.
23.Reiner Z. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk? Curr Atheroscler Rep. 2019;21(4):14.
24.Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochemical and biophysical research communications. 2002;296(5):1051-1057.
25.Herbst KL, Amory JK, Brunzell JD, Chansky HA, Bremner WJ. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Physiol Endocrinol Metab. 2003;284(6):E1112-1118.
26.Turhan S, Tulunay C, Gulec S, et al. The association between androgen levels and premature coronary artery disease in men. Coronary artery disease. 2007;18(3):159-162.
27.Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. Journal of lipid research. 2004;45(9):1583-1593.
28.Reaven PD, Witztum JL. Oxidized low density lipoproteins in atherogenesis: role of dietary modification. Annu Rev Nutr. 1996;16:51-71.
29.Steinberg D. The LDL modification hypothesis of atherogenesis: an update. Journal of lipid research. 2009;50 Suppl:S376-381.
30.Chouinard JA, Grenier G, Khalil A, Vermette P. Oxidized-LDL induce morphological changes and increase stiffness of endothelial cells. Experimental cell research. 2008;314(16):3007-3016.
31.Fournet M, Bonte F, Desmouliere A. Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging. Aging Dis. 2018;9(5):880-900.
32.Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol. 2012;4(4):90-102.
33.Havranek EP. Primary prevention of CHD: nine ways to reduce risk. American family physician. 1999;59(6):1455-1463, 1466.
34.Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. The open cardiovascular medicine journal. 2011;5:76-84.
35.Wanjia X, Chenggang W, Aihong W, et al. A high normal TSH level is associated with an atherogenic lipid profile in euthyroid non-smokers with newly diagnosed asymptomatic coronary heart disease. Lipids in health and disease. 2012;11:44.
36.van Tienhoven-Wind LJ, Dullaart RP. Low-normal thyroid function and novel cardiometabolic biomarkers. Nutrients. 2015;7(2):1352-1377.
37.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18(6):499-502.
38.Bhatt DL. Non-HDL cholesterol explained. Heart Health Publishing online. https://www.health.harvard.edu/heart-health/non-hdl-cholesterol-explained. 1/2018. Accessed 5/31/2019.
39.Wolska A, Remaley A. Lipoprotein Subfraction Analysis. Clinical Laboratory News online. https://www.aacc.org/publications/cln/articles/2017/january/lipoprotein-subfractionation-analysis. 1/3/2017. Accessed 5/31/2019. 2017.
40.Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. The New England journal of medicine. 2007;356(23):2388-2398.
41.Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J. 2002;23(8):620-626.
42.Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine. 2008;359(21):2195-2207.
43.Daviglus ML, Stamler J, Pirzada A, et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. Jama. 2004;292(13):1588-1592.
44.Sobal G, Menzel J, Sinzinger H. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. Prostaglandins Leukot Essent Fatty Acids. 2000;63(4):177-186.
45.Nivoit P, Wiernsperger N, Moulin P, Lagarde M, Renaudin C. Effect of glycated LDL on microvascular tone in mice: a comparative study with LDL modified in vitro or isolated from diabetic patients. Diabetologia. 2003;46(11):1550-1558.
46.Toma L, Stancu CS, Botez GM, Sima AV, Simionescu M. Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochemical and biophysical research communications. 2009;390(3):877-882.
47.Dong Y, Wu Y, Wu M, et al. Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase. Journal of cellular and molecular medicine. 2009;13(9a):2899-2910.
48.Calvo C. [Non-enzymatic glycosylation of lipoproteins in the pathogenesis of atherosclerosis in diabetics]. Revista medica de Chile. 1997;125(4):460-465.
49.Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol. 2011;22(4):254-261.
50.Miceli N, Mondello MR, Monforte MT, et al. Hypolipidemic effects of Citrus bergamia Risso et Poiteau juice in rats fed a hypercholesterolemic diet. J Agric Food Chem. 2007;55(26):10671-10677.
51.American Heart Association. Healthy Cooking Oils. https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/fats/healthy-cooking-oils. Published 2018. Updated 04/24/2018. Accessed 04/30/2019.
52.Association AH. The American Heart Association Diet and Lifestyle Recommendations. https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/nutrition-basics/aha-diet-and-lifestyle-recommendations. Published 2015. Updated 08/15/2015. Accessed 04/30/2019.
53.Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation. 2017;136(3):e1-e23.
54.LANE MA, BLACK A, INGRAM DK, ROTH GS. Calorie Restriction in Nonhuman Primates: Implications for Age-Related Disease Risk. Journal of Anti-Aging Medicine. 1998;1(4):315-326.
55.Walford RL, Mock D, Verdery R, MacCallum T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. The journals of gerontology Series A, Biological sciences and medical sciences. 2002;57(6):B211-224.
56.Meyer TE, Kovacs SJ, Ehsani AA, Klein S, Holloszy JO, Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. Journal of the American College of Cardiology. 2006;47(2):398-402.
57.Fontana L, Klein S, Holloszy JO, Premachandra BN. Effect of long-term calorie restriction with adequate protein and micronutrients on thyroid hormones. J Clin Endocrinol Metab. 2006;91(8):3232-3235.
58.Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A. 2004;101(17):6659-6663.
59.Stewart TM, Bhapkar M, Das S, et al. Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy Phase 2 (CALERIE Phase 2) screening and recruitment: methods and results. Contemporary clinical trials. 2013;34(1):10-20.
60.Lefevre M, Redman LM, Heilbronn LK, et al. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis. 2009;203(1):206-213.
61.Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation.0(0):CIR.0000000000000678.
62.Nassef Y, Lee KJ, Nfor ON, Tantoh DM, Chou MC, Liaw YP. The Impact of Aerobic Exercise and Badminton on HDL Cholesterol Levels in Adult Taiwanese. Nutrients. 2019;11(3).
63.Cho AR, Moon JY, Kim S, et al. Effects of alternate day fasting and exercise on cholesterol metabolism in overweight or obese adults: A pilot randomized controlled trial. Metabolism: clinical and experimental. 2019;93:52-60.
64.Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of Diet and Exercise in Men and Postmenopausal Women with Low Levels of HDL Cholesterol and High Levels of LDL Cholesterol. New England Journal of Medicine. 1998;339(1):12-20.
65.Glenney SS, Brockemer DP, Ng AC, Smolewski MA, Smolgovskiy VM, Lepley AS. Effect of Exercise Training on Cardiac Biomarkers in At-Risk Populations: A Systematic Review. J Phys Act Health. 2017;14(12):968-989.
66.Patel H, Alkhawam H, Madanieh R, Shah N, Kosmas CE, Vittorio TJ. Aerobic vs anaerobic exercise training effects on the cardiovascular system. World journal of cardiology. 2017;9(2):134-138.
67.Barter PJ, Rye KA. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? Circulation. 2006;113(12):1553-1555.
68.Devaraj S, Siegel D, Jialal I. Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP? Curr Atheroscler Rep. 2011;13(1):31-42.
69.Fung EC, Crook MA. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovascular therapeutics. 2012;30(5):e212-218.
70.Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve. 2010;42(4):469-479.
71.Hammersley D, Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Therapeutic advances in chronic disease. 2017;8(1):4-11.
72.Davidson MH. Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr Atheroscler Rep. 2011;13(1):95-100.
73.Toth PP, Patti AM, Giglio RV, et al. Management of Statin Intolerance in 2018: Still More Questions Than Answers. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2018;18(3):157-173.
74.Brown JE, Rice-Evans CA. Luteolin-rich artichoke extract protects low density lipoprotein from oxidation in vitro. Free Radic Res. 1998;29(3):247-255.
75.Englisch W, Beckers C, Unkauf M, Ruepp M, Zinserling V. Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung. 2000;50(3):260-265.
76.Bundy R, Walker AF, Middleton RW, Wallis C, Simpson HC. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. Phytomedicine. 2008;15(9):668-675.
77.Rondanelli M, Giacosa A, Opizzi A, et al. Beneficial effects of artichoke leaf extract supplementation on increasing HDL-cholesterol in subjects with primary mild hypercholesterolaemia: a double-blind, randomized, placebo-controlled trial. International journal of food sciences and nutrition. 2013;64(1):7-15.
78.Nazni P, Vijayakumar TP, Alagianambi P, Amirthaveni M. Hypoglycemic and hypolipidemic effect of Cynara scolymus among selected type 2 diabetic individuals. Pak J Nutr. 2006;5(2):147-151.
79.Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. Journal of the American College of Cardiology. 2000;35(3):640-646.
80.McCarty MF. Inhibition of acetyl-CoA carboxylase by cystamine may mediate the hypotriglyceridemic activity of pantethine. Med Hypotheses. 2001;56(3):314-317.
81.Bertolini S, Donati C, Elicio N, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. Int J Clin Pharmacol Ther Toxicol. 1986;24(11):630-637.
82.Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis. 1984;50(1):73-83.
83.Donati C, Bertieri RS, Barbi G. [Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients]. Clin Ter. 1989;128(6):411-422.
84.Tonutti L, Taboga C, Noacco C. [Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia]. Minerva Med. 1991;82(10):657-663.
85.Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr Res. 2011;31(8):608-615.
86.Yadav SS, Singh MK, Singh PK, Kumar V. Traditional knowledge to clinical trials: A review on therapeutic actions of Emblica officinalis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2017;93:1292-1302.
87.Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. International journal of food sciences and nutrition. 2011;62(6):609-616.
88.Kim HY, Okubo T, Juneja LR, Yokozawa T. The protective role of amla (Emblica officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. The British journal of nutrition. 2010;103(4):502-512.
89.Gopa B, Bhatt J, Hemavathi KG. A comparative clinical study of hypolipidemic efficacy of Amla (Emblica officinalis) with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor simvastatin. Indian journal of pharmacology. 2012;44(2):238-242.
90.Usharani P, Fatima N, Muralidhar N. Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study. Diabetes, metabolic syndrome and obesity : targets and therapy. 2013;6:275-284.
91.Khanna S, Das A, Spieldenner J, Rink C, Roy S. Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults. Journal of medicinal food. 2015;18(4):415-420.
92.Reinhart KM, Talati R, White CM, Coleman CI. The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Res Rev. 2009;22(1):39-48.
93.Khoo YS, Aziz Z. Garlic supplementation and serum cholesterol: a meta-analysis. J Clin Pharm Ther. 2009;34(2):133-145.
94.Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med. 2000;133(6):420-429.
95.Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. Nutrition reviews. 2013;71(5):282-299.
96.Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC cardiovascular disorders. 2008;8:13.
97.Gauhar R, Hwang SL, Jeong SS, et al. Heat-processed Gynostemma pentaphyllum extract improves obesity in ob/ob mice by activating AMP-activated protein kinase. Biotechnology letters. 2012;34(9):1607-1616.
98.Nguyen PH, Gauhar R, Hwang SL, et al. New dammarane-type glucosides as potential activators of AMP-activated protein kinase (AMPK) from Gynostemma pentaphyllum. Bioorganic & medicinal chemistry. 2011;19(21):6254-6260.
99.Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. The American journal of physiology. 1999;277(1 Pt 1):E1-10.
100.Park SH, Huh TL, Kim SY, et al. Antiobesity effect of Gynostemma pentaphyllum extract (actiponin): a randomized, double-blind, placebo-controlled trial. Obesity (Silver Spring). 2014;22(1):63-71.
101.Dong Y, Zhang M, Wang S, et al. Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes. 2010;59(6):1386-1396.
102.Umeno A, Horie M, Murotomi K, Nakajima Y, Yoshida Y. Antioxidative and Antidiabetic Effects of Natural Polyphenols and Isoflavones. Molecules (Basel, Switzerland). 2016;21(6).
103.Devi KP, Rajavel T, Nabavi SF, et al. Hesperidin: A promising anticancer agent from nature. Industrial crops and products. 2015;76:582-589.
104.Li C, Schluesener H. Health-promoting effects of the citrus flavanone hesperidin. Crit Rev Food Sci Nutr. 2017;57(3):613-631.
105.Roohbakhsh A, Parhiz H, Soltani F, Rezaee R, Iranshahi M. Neuropharmacological properties and pharmacokinetics of the citrus flavonoids hesperidin and hesperetin--a mini-review. Life Sci. 2014;113(1-2):1-6.
106.Jia S, Hu Y, Zhang W, et al. Hypoglycemic and hypolipidemic effects of neohesperidin derived from Citrus aurantium L. in diabetic KK-A(y) mice. Food Funct. 2015;6(3):878-886.
107.Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011;96(5):E782-792.
108.Zhang J, Sun C, Yan Y, et al. Purification of naringin and neohesperidin from Huyou (Citrus changshanensis) fruit and their effects on glucose consumption in human HepG2 cells. Food Chem. 2012;135(3):1471-1478.
109.Homayouni F, Haidari F, Hedayati M, Zakerkish M, Ahmadi K. Hesperidin Supplementation Alleviates Oxidative DNA Damage and Lipid Peroxidation in Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Phytother Res. 2017.
110.Sun Q, Wedick NM, Tworoger SS, et al. Urinary Excretion of Select Dietary Polyphenol Metabolites Is Associated with a Lower Risk of Type 2 Diabetes in Proximate but Not Remote Follow-Up in a Prospective Investigation in 2 Cohorts of US Women. J Nutr. 2015;145(6):1280-1288.
111.Adab Z, Eghtesadi S, Vafa MR, et al. Effect of turmeric on glycemic status, lipid profile, hs-CRP, and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients. Phytother Res. 2019.
112.Salden BN, Troost FJ, de Groot E, et al. Randomized clinical trial on the efficacy of hesperidin 2S on validated cardiovascular biomarkers in healthy overweight individuals. Am J Clin Nutr. 2016;104(6):1523-1533.
113.Haidari F, Heybar H, Jalali MT, Ahmadi Engali K, Helli B, Shirbeigi E. Hesperidin supplementation modulates inflammatory responses following myocardial infarction. J Am Coll Nutr. 2015;34(3):205-211.
114.Amir Shaghaghi M, Abumweis SS, Jones PJ. Cholesterol-lowering efficacy of plant sterols/stanols provided in capsule and tablet formats: results of a systematic review and meta-analysis. Journal of the Academy of Nutrition and Dietetics. 2013;113(11):1494-1503.
115.Salo P, Wester I. Low-fat formulations of plant stanols and sterols. The American journal of cardiology. 2005;96(1a):51d-54d.
116.Weingartner O, Bohm M, Laufs U. Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J. 2009;30(4):404-409.
117.Calpe-Berdiel L, Escola-Gil JC, Blanco-Vaca F. New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism. Atherosclerosis. 2009;203(1):18-31.
118.Shrestha S, Freake HC, McGrane MM, Volek JS, Fernandez ML. A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake. J Nutr. 2007;137(5):1165-1170.
119.Badimon L, Vilahur G, Padro T. Nutraceuticals and atherosclerosis: human trials. Cardiovascular therapeutics. 2010;28(4):202-215.
120.Normen L, Holmes D, Frohlich J. Plant sterols and their role in combined use with statins for lipid lowering. Current opinion in investigational drugs (London, England : 2000). 2005;6(3):307-316.
121.Berger A, Jones PJ, Abumweis SS. Plant sterols: factors affecting their efficacy and safety as functional food ingredients. Lipids in health and disease. 2004;3:5.
122.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama. 2001;285(19):2486-2497.
123.Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(10):2186-2191.
124.Banach M, Patti AM, Giglio RV, et al. The Role of Nutraceuticals in Statin Intolerant Patients. Journal of the American College of Cardiology. 2018;72(1):96-118.
125.Ulbricht C, Basch E, Szapary P, et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complementary therapies in medicine. 2005;13(4):279-290.
126.Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther. 1994;8(4):659-664.
127.Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. Jama. 2003;290(6):765-772.
128.Nohr LA, Rasmussen LB, Straand J. Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study. Complementary therapies in medicine. 2009;17(1):16-22.
129.Patti AM, Al-Rasadi K, Katsiki N, et al. Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome. Angiology. 2015;66(9):856-861.
130.Das S, Datta A, Bagchi C, Chakraborty S, Mitra A, Tripathi SK. A Comparative Study of Lipid-Lowering Effects of Guggul and Atorvastatin Monotherapy in Comparison to Their Combination in High Cholesterol Diet-Induced Hyperlipidemia in Rabbits. Journal of dietary supplements. 2016;13(5):495-504.
131.Amato A, Caldara GF, Nuzzo D, et al. NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet. Nutrients. 2017;9(5).
132.Anderson JW, Randles KM, Kendall CW, Jenkins DJ. Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr. 2004;23(1):5-17.
133.Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30-42.
134.AbuMweis SS, Jew S, Ames NP. beta-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. European journal of clinical nutrition. 2010;64(12):1472-1480.
135.Baker WL, Tercius A, Anglade M, White CM, Coleman CI. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann Nutr Metab. 2009;55(4):368-374.
136.Zhu X, Sun X, Wang M, et al. Quantitative assessment of the effects of beta-glucan consumption on serum lipid profile and glucose level in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis. 2015;25(8):714-723.
137.Jarosz PA, Fletcher E, Elserafy E, Artiss JD, Jen KL. The effect of alpha-cyclodextrin on postprandial lipid and glycemic responses to a fat-containing meal. Metabolism: clinical and experimental. 2013;62(10):1443-1447.
138.Artiss JD, Brogan K, Brucal M, Moghaddam M, Jen KL. The effects of a new soluble dietary fiber on weight gain and selected blood parameters in rats. Metabolism: clinical and experimental. 2006;55(2):195-202.
139.Wagner EM, Catherine Jen KL, Artiss JD, Remaley AT. Dietary alpha-cyclodextrin lowers LDL-C and alters plasma fatty acid profile in LDLr-KO mice on a high-fat diet. Metabolism: clinical and experimental. 2008;57(8):1046-1051.
140.Gallaher DD, Gallaher CM, Plank DW. Alpha-cyclodextrin selectively increases fecal excretion of saturated fats. In: Federation of American Societies for Experimental Biology; 2007.
141.Grunberger G, Jen KL, Artiss JD. The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre. Diabetes Metab Res Rev. 2007;23(1):56-62.
142.Comerford KB, Artiss JD, Jen KLC, Karakas SE. The Beneficial Effects α-Cyclodextrin on Blood Lipids and Weight Loss in Healthy Humans. Obesity. 2011;19(6):1200-1204.
143.Amar MJ, Kaler M, Courville AB, Shamburek R, Sampson M, Remaley AT. Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids. Lipids in health and disease. 2016;15(1):115.
144.Sakurai T, Sakurai A, Chen Y, et al. Dietary α-cyclodextrin reduces atherosclerosis and modifies gut flora in apolipoprotein E-deficient mice. Mol Nutr Food Res. 2017;61(8).
145.Sangle GV, Chowdhury SK, Xie X, Stelmack GL, Halayko AJ, Shen GX. Impairment of mitochondrial respiratory chain activity in aortic endothelial cells induced by glycated low-density lipoprotein. Free radical biology & medicine. 2010;48(6):781-790.
146.Roy Chowdhury SK, Sangle GV, Xie X, Stelmack GL, Halayko AJ, Shen GX. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells. Am J Physiol Endocrinol Metab. 2010;298(1):E89-98.
147.Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007;7 Suppl:S168-174.
148.Tóth Š, Šajty M, Pekárová T, et al. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. Journal of basic and clinical physiology and pharmacology. 2017;28(4):327-336.
149.Jorat MV, Tabrizi R, Mirhosseini N, et al. The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Lipids in health and disease. 2018;17(1):230.
150.Sahebkar A, Simental-Mendía LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. Pharmacol Res. 2016;105:198-209.
151.Karppi J, Nurmi T, Kurl S, Rissanen TH, Nyyssonen K. Lycopene, lutein and beta-carotene as determinants of LDL conjugated dienes in serum. Atherosclerosis. 2010;209(2):565-572.
152.Ried K, Fakler P. Protective effect of lycopene on serum cholesterol and blood pressure: Meta-analyses of intervention trials. Maturitas. 2011;68(4):299-310.
153.Fuhrman B, Elis A, Aviram M. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Biochemical and biophysical research communications. 1997;233(3):658-662.
154.Mao M, Lei H, Liu Q, et al. Lycopene inhibits neointimal hyperplasia through regulating lipid metabolism and suppressing oxidative stress. Molecular medicine reports. 2014;10(1):262-268.
155.Aidoud A, Ammouche A, Garrido M, Rodriguez AB. Effect of lycopene-enriched olive and argan oils upon lipid serum parameters in Wistar rats. Journal of the science of food and agriculture. 2014;94(14):2943-2950.
156.Cheng HM, Koutsidis G, Lodge JK, Ashor A, Siervo M, Lara J. Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis. Atherosclerosis. 2017;257:100-108.
157.Badiou S, Cristol JP, Morena M, et al. Vitamin E supplementation increases LDL resistance to ex vivo oxidation in hemodialysis patients. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition. 2003;73(4):290-296.
158.Tesoriere L, D'Arpa D, Butera D, et al. Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients. Free Radic Res. 2001;34(5):529-540.
159.Li D, Saldeen T, Romeo F, Mehta JL. Relative Effects of alpha- and gamma-Tocopherol on Low-Density Lipoprotein Oxidation and Superoxide Dismutase and Nitric Oxide Synthase Activity and Protein Expression in Rats. J Cardiovasc Pharmacol Ther. 1999;4(4):219-226.
160.McCarty MF. Gamma-tocopherol may promote effective no synthase function by protecting tetrahydrobiopterin from peroxynitrite. Med Hypotheses. 2007;69(6):1367-1370.
161.Saito F, Iwamoto S, Yamauchi R. Reaction products of gamma-tocopherol with (E)-4-oxo-2-nonenal in acidic acetonitrile. Bioscience, biotechnology, and biochemistry. 2010;74(1):168-174.
162.Singh I, Turner AH, Sinclair AJ, Li D, Hawley JA. Effects of gamma-tocopherol supplementation on thrombotic risk factors. Asia Pac J Clin Nutr. 2007;16(3):422-428.
163.Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88(1):38-50.
164.Onakpoya I, Spencer E, Heneghan C, Thompson M. The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(8):823-836.
165.Alves Ferreira M, Oliveira Gomes AP, Guimarães de Moraes AP, et al. Green tea extract outperforms metformin in lipid profile and glycaemic control in overweight women: A double-blind, placebo-controlled, randomized trial. Clinical nutrition ESPEN. 2017;22:1-6.
166.Fujita H, Yamagami T. Antihypercholesterolemic effect of Chinese black tea extract in human subjects with borderline hypercholesterolemia. Nutr Res. 2008;28(7):450-456.
167.Imran A, Butt MS, Arshad MS, et al. Exploring the potential of black tea based flavonoids against hyperlipidemia related disorders. Lipids in health and disease. 2018;17(1):57.
168.Aviram M, Dornfeld L, Kaplan M, et al. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. Drugs under experimental and clinical research. 2002;28(2-3):49-62.
169.Sezer ED, Akcay YD, Ilanbey B, Yildirim HK, Sozmen EY. Pomegranate wine has greater protection capacity than red wine on low-density lipoprotein oxidation. Journal of medicinal food. 2007;10(2):371-374.
170.Esmaillzadeh A, Tahbaz F, Gaieni I, Alavi-Majd H, Azadbakht L. Cholesterol-lowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition. 2006;76(3):147-151.
171.Fuhrman B, Volkova N, Aviram M. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J Nutr Biochem. 2005;16(9):570-576.
172.Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004;23(3):423-433.
173.Kojadinovic MI, Arsic AC, Debeljak-Martacic JD, et al. Consumption of pomegranate juice decreases blood lipid peroxidation and levels of arachidonic acid in women with metabolic syndrome. Journal of the science of food and agriculture. 2017;97(6):1798-1804.
174.Shema-Didi L, Kristal B, Sela S, Geron R, Ore L. Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients? Nutr J. 2014;13:18.
175.Hosseini B, Saedisomeolia A, Wood LG, Yaseri M, Tavasoli S. Effects of pomegranate extract supplementation on inflammation in overweight and obese individuals: A randomized controlled clinical trial. Complementary therapies in clinical practice. 2016;22:44-50.
176.Ramirez-Boscá A, Soler A, Gutierrez MAC, Alvarez JL, Almagro EQ. Antioxidant curcuma extracts decrease the blood lipid peroxide levels of human subjects. Age. 1995;18(4):167-169.
177.Ramirez Bosca A, Carrion Gutierrez MA, Soler A, et al. Effects of the antioxidant turmeric on lipoprotein peroxides: Implications for the prevention of atherosclerosis. Age (Omaha). 1997;20(3):165-168.
178.Ramirez Bosca A, Soler A, Carrion-Gutierrez MA, et al. An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen. Mech Ageing Dev. 2000;114(3):207-210.
179.Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol. 2009;133(2):145-151.
180.Dou X, Fan C, Wo L, Yan J, Qian Y, Wo X. Curcumin up-regulates LDL receptor expression via the sterol regulatory element pathway in HepG2 cells. Planta Med. 2008;74(11):1374-1379.
181.Peschel D, Koerting R, Nass N. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem. 2007;18(2):113-119.
182.Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian journal of physiology and pharmacology. 1992;36(4):273-275.
183.Alwi I, Santoso T, Suyono S, et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta medica Indonesiana. 2008;40(4):201-210.
184.Baum L, Cheung SK, Mok VC, et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacological research : the official journal of the Italian Pharmacological Society. 2007;56(6):509-514.
185.Qin S, Huang L, Gong J, et al. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr J. 2017;16(1):68.
186.Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014;28(12):1770-1777.
187.Pizzini A, Lunger L, Demetz E, et al. The Role of Omega-3 Fatty Acids in Reverse Cholesterol Transport: A Review. Nutrients. 2017;9(10).
188.Simopoulos AP. Evolutionary Aspects of the Dietary Omega-6/Omega-3 Fatty Acid Ratio: Medical Implications. In: Alvergne A, Jenkinson C, Faurie C, eds. Evolutionary Thinking in Medicine: From Research to Policy and Practice. Cham: Springer International Publishing; 2016:119-134.
189.Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. Journal of clinical lipidology. 2012;6(1):5-18.
190.Allaire J, Vors C, Tremblay AJ, et al. High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study. J Clin Endocrinol Metab. 2018;103(8):2909-2917.
191.Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England journal of medicine. 2019;380(1):11-22.
192.Wu Y, Zhang Q, Ren Y, Ruan Z. Effect of probiotic Lactobacillus on lipid profile: A systematic review and meta-analysis of randomized, controlled trials. PLoS One. 2017;12(6):e0178868.
193.DiRienzo DB. Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets. Nutrition reviews. 2014;72(1):18-29.
194.Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. The British journal of nutrition. 2012;107(10):1505-1513.
195.Semekovich CF, Goldman L. Goldman-Cecil Medicine. Twenty-fifth edition. Chapter 206: Disorders of Lipid Metabolism. 1389-1397..e.3. Copyright 2016 by Saunders, an imprint of Elsevier Inc. www.clinicalkey.com. Accessed 7/7/2016.
196.Lu M, Lu Q, Zhang Y, Tian G. ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity(). Journal of biomedical research. 2011;25(4):266-273.
197.Walldius G, Frank S, Kostner G. Biochemistry, Genetics, and Molecular Biology. Chapter 5: The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk. http://www.intechopen.com/books/lipoproteins-role-in-health-and-diseases/the-apob-apoa-i-ratio-is-a-strong-predictor-of-cardiovascular-risk. 10/3/2012. Accessed 7/7/2016.
198.Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. European journal of clinical nutrition. 2012;66(11):1234-1241.
199.Jones ML, Martoni CJ, Ganopolsky JG, Sulemankhil I, Ghali P, Prakash S. Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial. Expert Opin Biol Ther. 2013;13(12):1643-1651.
200.Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial. J Clin Endocrinol Metab. 2013;98(7):2944-2951.
201.Staels B, Fonseca VA. Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009;32(Suppl 2):S237-245.
202.Kumar M, Nagpal R, Kumar R, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Experimental diabetes research. 2012;2012:902917.
203.Cho YA, Kim J. Effect of Probiotics on Blood Lipid Concentrations: A Meta-Analysis of Randomized Controlled Trials. Medicine. 2015;94(43):e1714.
204.Sun J, Buys N. Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2015;47(6):430-440.
205.Zhao H, Song A, Zhang Y, Shu L, Song G, Ma H. Effect of Resveratrol on Blood Lipid Levels in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Obesity (Silver Spring). 2019;27(1):94-102.
206.He J, Zhang F, Han Y. Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: A meta-analysis of RCTs. Medicine. 2017;96(51):e9166.
207.Brighenti F, Casiraghi MC, Canzi E, Ferrari A. Effect of consumption of a ready-to-eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers. European journal of clinical nutrition. 1999;53(9):726-733.
208.Li S, Guerin-Deremaux L, Pochat M, Wils D, Reifer C, Miller LE. NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in overweight men: a double-blind, randomized, placebo-controlled study. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2010;35(6):773-782.
209.Cunningham E. Is red yeast rice safe and effective for lowering serum cholesterol? J Am Diet Assoc. 2011;111(2):324.
210.Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese medicine. 2006;1:4.
211.Moriarty PM, Roth EM, Karns A, et al. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. Journal of clinical lipidology. 2014;8(6):568-575.
212.Shang Q, Liu Z, Chen K, Xu H, Liu J. A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evidence-based complementary and alternative medicine : eCAM. 2012;2012:636547.
213.Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. The American journal of cardiology. 2008;101(12):1689-1693.
214.Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150(12):830-839, w147-839.
215.Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. The American journal of cardiology. 2010;105(2):198-204.
216.Kasliwal RR, Bansal M, Gupta R, et al. ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. Nutrition (Burbank, Los Angeles County, Calif). 2016;32(7-8):767-776.
217.Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170(19):1722-1727.
218.Toth PP, Patti AM, Nikolic D, et al. Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. Frontiers in pharmacology. 2015;6:299.
219.Cai Y, Xing G, Shen T, Zhang S, Rao J, Shi R. Effects of 12-week supplementation of Citrus bergamia extracts-based formulation CitriCholess on cholesterol and body weight in older adults with dyslipidemia: a randomized, double-blind, placebo-controlled trial. Lipids in health and disease. 2017;16(1):251.
220.Gliozzi M, Walker R, Muscoli S, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol. 2013;170(2):140-145.
221.D'Andrea E, Hey SP, Ramirez CL, Kesselheim AS. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019;2(4):e192224.
222.Kamanna VS, Kashyap ML. Mechanism of Action of Niacin. The American journal of cardiology. 2008;101(8, Supplement):S20-S26.
223.Garg A, Sharma A, Krishnamoorthy P, et al. Role of Niacin in Current Clinical Practice: A Systematic Review. Am J Med. 2017;130(2):173-187.
224.Neelakantan N, Seah JYH, van Dam RM. The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Clinical Trials. Circulation. 2020.
225.Hoppstädter J, Valbuena Perez JV, Linnenberger R, et al. The glucocorticoid-induced leucine zipper mediates statin-induced muscle damage. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2020:10.1096/fj.201902557RRR.
226.tctMD. FDA Approves New Lipid-Lowering Drug, Bempedoic Acid. https://www.tctmd.com/news/fda-approves-new-lipid-lowering-drug-bempedoic-acid. Published 2020. Accessed February 26, 2020.
227.Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780-1788.
228.Lalwani ND, Hanselman JC, MacDougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial. Journal of Clinical Lipidology. 2019;13(4):568-579.
229.Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62(13):1154-1162.
230.Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European journal of preventive cardiology. 2019:2047487319864671-2047487319864671.
231.Khan SU, Michos ED. Bempedoic acid and ezetimibe – better together. European Journal of Preventive Cardiology. 2019:2047487319864672.
232.Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. New England Journal of Medicine. 2019;380(11):1022-1032.
233.Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Current atherosclerosis reports. 2016;18(10):61-61.
234.Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019;30(1):1-9.
235.Reduction of Revascularizations in Patients with Hypertriglyceridemia With Icosapent Ethyl: Insights From REDUCE-IT REVASC [press release]. Society for Cardiovascular Angiography and Interventions.2020.
236.Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is Over. JAMA Cardiol. Nov 13 2021;doi:10.1001/jamacardio.2021.5080
237.Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology. 2021/03/23/ 2021;77(11):1439-1450. doi:https://doi.org/10.1016/j.jacc.2021.01.027
238.StatPearls. Biochemistry, Apolipoprotein B. Accessed 12/29/2021, https://www.statpearls.com/articlelibrary/viewarticle/17778
239.Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2019;41(1):111-188. doi:10.1093/eurheartj/ehz455
240.Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiology. 2021;doi:10.1001/jamacardio.2021.5083
       
        </p>

</div>
<script>
        
    </script>
</body>
</html>